Tag: Light-Chain Amyloidosis

Subcutaneous daratumumab + cyclophosphamide, bortezomib, and dexamethasone in patients with newly diagnosed amyloid light chain amyloidosis

Presented By

Prof. Raymond Comenzo, Tufts University, USA

Trial

Phase 3, ANDROMEDA

Conference

EHA 2019